Vis enkel innførsel

dc.contributor.authorHarneshaug, Magnus
dc.contributor.authorKirkhus, Lene
dc.contributor.authorSaltyte Benth, Jurate
dc.contributor.authorGrønberg, Bjørn Henning
dc.contributor.authorBergh, Sverre
dc.contributor.authorWhist, Jon Elling
dc.contributor.authorRostoft, Siri
dc.contributor.authorJordhøy, Marit Slaaen
dc.identifier.citationJournal of Geriatric Oncology. 2018, .en_US
dc.description.abstractIntroduction: As frailty is associated with inflammation, biomarkers of inflammation may represent objective measures that could facilitate the identification of frailty. Glasgow prognostic score (GPS), combines C-reactive protein (CRP) and albumin, and is scored from 0 to 2 points. Higher score indicates a higher degree of inflammation. Objectives: To investigate whether (1) GPS is associated with frailty, (2) GPS could be used to screen for frailty, (3) IL-6 and TNF-α add to the accuracy of GPS as a screening tool, and (4) GPS adds prognostic information in frail older patients with cancer. Methods: Prospective, observational study of 255 patients ≥70 years with solid malignant tumours referred for medical cancer treatment. At baseline, frail patients were identified by a modified Geriatric Assessment (mGA), and blood samples were collected. Results: Mean age was 76.7 years, 49.8% were frail, and 56.1% had distant metastases. The proportion of frail patients increased with higher GPS (GPS zero: 43.2%, GPS one: 52.7%, GPS two: 94.7%). GPS two was significantly associated with frailty (OR 18.5), independent of cancer type, stage, BMI and the use of anti-inflammatory drugs. The specificity of GPS was high (99%), but the sensitivity was low (14%). Frail patients with GPS two had poorer survival than patients with GPS zero-one. TNF-α and IL-6 did not improve the accuracy of GPS when screening for frailty. Conclusion: Frailty and GPS two are strongly associated, and GPS two is a significant prognostic factor in frail, older patients with cancer. The inflammatory biomarkers investigated are not suitable screening tools for frailty.en_US
dc.description.sponsorshipThis study was funded by Innlandet Hospital Trust (0303 150337).en_US
dc.rightsNavngivelse-Ikkekommersiell-DelPåSammeVilkår 4.0 Internasjonal*
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.subjectGlasgow prognostic score (GPS)en_US
dc.subjectC-reactive protein (CRP)en_US
dc.subjectmalignant tumoursen_US
dc.subjectblood samplesen_US
dc.subjectFrailty and GPSen_US
dc.subjectpoorer survivalen_US
dc.subjectolder patientsen_US
dc.subjectGeriatric Assessment (mGA)en_US
dc.subjectmedical cancer treatmenten_US
dc.titleScreening for frailty among older patients with cancer using blood biomarkers of inflammationen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.rights.holderCopyright © 2018 Elsevier Inc. All rights reserved.en_US
dc.source.journalJournal of Geriatric Oncologyen_US

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse-Ikkekommersiell-DelPåSammeVilkår 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse-Ikkekommersiell-DelPåSammeVilkår 4.0 Internasjonal